0001209191-23-053558.txt : 20231025 0001209191-23-053558.hdr.sgml : 20231025 20231025162841 ACCESSION NUMBER: 0001209191-23-053558 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20231023 FILED AS OF DATE: 20231025 DATE AS OF CHANGE: 20231025 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Monahan Joseph CENTRAL INDEX KEY: 0001861790 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37581 FILM NUMBER: 231346359 MAIL ADDRESS: STREET 1: C/O ACLARIS THERAPEUTICS, INC. STREET 2: 640 LEE ROAD, SUITE 200 CITY: WAYNE STATE: PA ZIP: 19087 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Aclaris Therapeutics, Inc. CENTRAL INDEX KEY: 0001557746 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 460571712 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 640 LEE ROAD STREET 2: SUITE 200 CITY: WAYNE STATE: PA ZIP: 19087 BUSINESS PHONE: 484-324-7933 MAIL ADDRESS: STREET 1: 640 LEE ROAD STREET 2: SUITE 200 CITY: WAYNE STATE: PA ZIP: 19087 4 1 doc4.xml FORM 4 SUBMISSION X0508 4 2023-10-23 0 0001557746 Aclaris Therapeutics, Inc. ACRS 0001861790 Monahan Joseph C/O ACLARIS THERAPEUTICS, INC. 640 LEE ROAD, SUITE 200 WAYNE PA 19087 0 1 0 0 Chief Scientific Officer 1 Common Stock 2023-10-23 4 S 0 6000 5.0767 D 129724 D Common Stock 193 I By Spouse These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 21, 2023. The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $4.97 to $5.24, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. /s/ Mark Ballantyne, Attorney-in-fact 2023-10-25